Methotrexate (CAS 59-05-2)/API

Methotrexate (CAS 59-05-2) is a high-purity pharmaceutical API classified as a potent antimetabolite, featuring a folic acid analog molecular structure engineered to target dihydrofolate reductase (DHFR). It irreversibly inhibits DHFR, blocking folic acid conversion to tetrahydrofolate—an essential cofactor for DNA, RNA, and protein synthesis—thus suppressing the proliferation of rapidly dividing cells (e.g., cancer cells, immune cells). This versatile API exhibits dual therapeutic potential, with well-established efficacy in both oncology and autoimmune disease management.

It caters to the core needs of oncology drug manufacturers, immunology research institutions, and clinical supply chains. Widely applied in developing treatments for breast cancer, leukemia, rheumatoid arthritis, and psoriasis, it aligns with the demand for multi-indication, evidence-based therapies. Produced under strict GMP standards, each batch undergoes rigorous purity and potency testing to meet international pharmacopoeia requirements, ensuring consistency for clinical and research use. For businesses prioritizing versatile, mechanism-driven pharmaceutical raw materials, this Methotrexate API serves as a critical component for advancing anticancer and autoimmune disease medication development.